Exploring clinical markers of Axon degeneration processes in Chemotherapy-induced peripheral neuropathy among young adults receiving vincristine or paclitaxel
To our knowledge, this is the first study to measure plasma NAD<sup>+</sup>, cADPR, and ADPR among patients receiving neurotoxic chemotherapy. Although, no meaningful changes in NAD<sup>+</sup>, cADPR, or cADPR/NAD<sup>+</sup> were observed among young adults receiving paclitaxel or vincristine. Future research in an adequately powered sample is needed to explore the clinical utility of biomarkers of axon degeneration among patients receiving neurotoxic chemotherapy to guide mechanistic research and novel CIPN treatments.
Authors
- Roy Freeman (ORCID: https://orcid.org/0000-0003-3976-6022)
- Donna Lynn Berry (ORCID: https://orcid.org/0000-0001-7935-2807)
- Emanuele Mazzola (ORCID: https://orcid.org/0000-0003-0561-7336)
- Marlise Rachael Luskin (ORCID: https://orcid.org/0000-0002-5781-4529)
- Maria F. Pazyra‐Murphy (ORCID: https://orcid.org/0009-0005-1076-4551)
- Jennifer A. Ligibel (ORCID: https://orcid.org/0000-0002-0633-3151)
- Robert Knoerl (ORCID: https://orcid.org/0000-0002-6996-5068)
- Marilyn J. Hammer (ORCID: https://orcid.org/0000-0002-9561-6144)
- A. Lindsay Frazier (ORCID: https://orcid.org/0000-0003-4748-8552)
- Birgitta Ryback (ORCID: https://orcid.org/0009-0006-7773-6878)
- Rosalind A. Segal (ORCID: https://orcid.org/0000-0001-9850-8432)
- Ann Steward LaCasce (ORCID: https://orcid.org/0000-0001-7349-0176)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Washington (US)
- University of Michigan (US)
- Neurobehavioral Systems (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- BMC Neurology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1186/s12883-024-03877-9
- Citations
- 6
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- National Institute of Nursing Research